Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 15 | 2026 | 51 | 2.400 |
Why?
|
| Antiviral Agents | 15 | 2026 | 92 | 1.560 |
Why?
|
| Lactation | 4 | 2026 | 37 | 1.480 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 23 | 1.280 |
Why?
|
| Liver Cirrhosis | 8 | 2026 | 32 | 1.190 |
Why?
|
| Hepatitis C | 7 | 2023 | 54 | 1.130 |
Why?
|
| Female | 54 | 2026 | 12193 | 0.970 |
Why?
|
| Humans | 65 | 2026 | 16832 | 0.970 |
Why?
|
| Stroke | 2 | 2026 | 297 | 0.930 |
Why?
|
| Child Development | 1 | 2026 | 58 | 0.930 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2026 | 98 | 0.900 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2026 | 353 | 0.880 |
Why?
|
| Liver Cirrhosis, Biliary | 4 | 2026 | 4 | 0.850 |
Why?
|
| Hawaii | 15 | 2026 | 62 | 0.850 |
Why?
|
| Coronary Disease | 1 | 2025 | 125 | 0.840 |
Why?
|
| Male | 36 | 2026 | 9556 | 0.810 |
Why?
|
| Adult | 31 | 2026 | 7255 | 0.750 |
Why?
|
| Sustained Virologic Response | 7 | 2026 | 14 | 0.720 |
Why?
|
| Retrospective Studies | 14 | 2026 | 2463 | 0.710 |
Why?
|
| Middle Aged | 31 | 2026 | 7515 | 0.690 |
Why?
|
| Aged | 23 | 2026 | 5901 | 0.640 |
Why?
|
| Risk Factors | 16 | 2026 | 3108 | 0.630 |
Why?
|
| Quality of Life | 4 | 2023 | 477 | 0.590 |
Why?
|
| Stress, Psychological | 1 | 2020 | 136 | 0.560 |
Why?
|
| United States | 19 | 2026 | 3858 | 0.550 |
Why?
|
| Health Status | 1 | 2020 | 256 | 0.540 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 23 | 0.520 |
Why?
|
| Suicide | 3 | 2024 | 114 | 0.520 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 34 | 0.510 |
Why?
|
| Vaccination | 3 | 2026 | 725 | 0.490 |
Why?
|
| Lung Neoplasms | 3 | 2025 | 268 | 0.470 |
Why?
|
| Incidence | 9 | 2026 | 1229 | 0.450 |
Why?
|
| Hepacivirus | 9 | 2024 | 41 | 0.450 |
Why?
|
| Ursodeoxycholic Acid | 3 | 2026 | 3 | 0.450 |
Why?
|
| Breast Feeding | 3 | 2026 | 112 | 0.440 |
Why?
|
| Mental Disorders | 3 | 2022 | 248 | 0.430 |
Why?
|
| Pregnancy | 5 | 2026 | 1555 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2026 | 677 | 0.410 |
Why?
|
| Patient Health Questionnaire | 2 | 2024 | 18 | 0.400 |
Why?
|
| Cholagogues and Choleretics | 2 | 2025 | 2 | 0.390 |
Why?
|
| Young Adult | 10 | 2026 | 2456 | 0.390 |
Why?
|
| Cataract Extraction | 1 | 2012 | 1 | 0.360 |
Why?
|
| Healthcare Disparities | 3 | 2026 | 213 | 0.360 |
Why?
|
| Cataract | 1 | 2012 | 9 | 0.360 |
Why?
|
| Adolescent | 20 | 2024 | 3464 | 0.360 |
Why?
|
| Electronic Health Records | 3 | 2026 | 702 | 0.350 |
Why?
|
| Rural Population | 1 | 2012 | 58 | 0.350 |
Why?
|
| Prevalence | 5 | 2023 | 785 | 0.340 |
Why?
|
| Coinfection | 2 | 2023 | 28 | 0.320 |
Why?
|
| Hepatitis B | 2 | 2023 | 43 | 0.310 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2022 | 4 | 0.310 |
Why?
|
| Mental Health | 2 | 2023 | 161 | 0.310 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 2 | 2007 | 5 | 0.300 |
Why?
|
| Diet | 3 | 2007 | 349 | 0.300 |
Why?
|
| Alkaline Phosphatase | 2 | 2025 | 8 | 0.280 |
Why?
|
| Cohort Studies | 12 | 2024 | 2396 | 0.270 |
Why?
|
| California | 5 | 2026 | 2244 | 0.270 |
Why?
|
| Absorptiometry, Photon | 4 | 2011 | 54 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2026 | 155 | 0.260 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 45 | 0.250 |
Why?
|
| Milk, Human | 1 | 2026 | 9 | 0.240 |
Why?
|
| Tetanus | 1 | 2026 | 23 | 0.240 |
Why?
|
| Portal Vein | 1 | 2026 | 1 | 0.240 |
Why?
|
| Venous Thrombosis | 1 | 2026 | 23 | 0.240 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2006 | 7 | 0.240 |
Why?
|
| Breast Neoplasms | 5 | 2017 | 913 | 0.230 |
Why?
|
| Language | 1 | 2026 | 51 | 0.230 |
Why?
|
| Feeding Behavior | 2 | 2007 | 161 | 0.230 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2026 | 42 | 0.230 |
Why?
|
| Postpartum Period | 1 | 2026 | 89 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2025 | 26 | 0.230 |
Why?
|
| Whooping Cough | 1 | 2026 | 71 | 0.230 |
Why?
|
| Heart Failure | 2 | 2025 | 403 | 0.230 |
Why?
|
| Mastitis | 1 | 2024 | 2 | 0.220 |
Why?
|
| Hepatitis B virus | 3 | 2023 | 22 | 0.220 |
Why?
|
| Surveys and Questionnaires | 5 | 2026 | 1204 | 0.220 |
Why?
|
| Infant, Newborn | 2 | 2026 | 828 | 0.210 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 84 | 0.210 |
Why?
|
| Obesity | 3 | 2024 | 811 | 0.210 |
Why?
|
| Clozapine | 1 | 2024 | 6 | 0.210 |
Why?
|
| Body Mass Index | 4 | 2022 | 925 | 0.210 |
Why?
|
| Guideline Adherence | 1 | 2025 | 155 | 0.210 |
Why?
|
| Myocardial Infarction | 1 | 2026 | 215 | 0.210 |
Why?
|
| Aminoisobutyric Acids | 1 | 2024 | 1 | 0.210 |
Why?
|
| Cyclopropanes | 1 | 2024 | 1 | 0.210 |
Why?
|
| Lactams, Macrocyclic | 1 | 2024 | 1 | 0.210 |
Why?
|
| Benzimidazoles | 1 | 2024 | 5 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2024 | 13 | 0.200 |
Why?
|
| Proline | 1 | 2024 | 5 | 0.200 |
Why?
|
| Leucine | 1 | 2024 | 4 | 0.200 |
Why?
|
| Adipose Tissue | 5 | 2011 | 63 | 0.200 |
Why?
|
| Antipsychotic Agents | 1 | 2024 | 50 | 0.200 |
Why?
|
| ras Proteins | 2 | 2014 | 20 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 31 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 52 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 9 | 0.190 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 13 | 0.190 |
Why?
|
| African Americans | 3 | 2020 | 394 | 0.190 |
Why?
|
| Treatment Outcome | 6 | 2025 | 1098 | 0.190 |
Why?
|
| Infant | 1 | 2026 | 1212 | 0.190 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 6 | 0.190 |
Why?
|
| Time Factors | 6 | 2026 | 989 | 0.180 |
Why?
|
| Ribavirin | 2 | 2019 | 6 | 0.180 |
Why?
|
| Breast | 3 | 2011 | 66 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2026 | 1047 | 0.180 |
Why?
|
| Carbonated Beverages | 3 | 2007 | 15 | 0.180 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 489 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 262 | 0.170 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 160 | 0.170 |
Why?
|
| Weight Gain | 1 | 2022 | 167 | 0.170 |
Why?
|
| Overweight | 1 | 2022 | 262 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 165 | 0.160 |
Why?
|
| Psychology | 1 | 2020 | 13 | 0.160 |
Why?
|
| Psychiatry | 1 | 2020 | 18 | 0.160 |
Why?
|
| Physician's Role | 1 | 2020 | 25 | 0.160 |
Why?
|
| Unemployment | 1 | 2020 | 12 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 21 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2023 | 1186 | 0.140 |
Why?
|
| Puberty | 2 | 2011 | 58 | 0.140 |
Why?
|
| Mental Health Services | 1 | 2020 | 132 | 0.140 |
Why?
|
| China | 2 | 2024 | 129 | 0.140 |
Why?
|
| Social Support | 1 | 2020 | 195 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 4 | 0.140 |
Why?
|
| Comorbidity | 1 | 2020 | 516 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 48 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 520 | 0.140 |
Why?
|
| Child | 8 | 2023 | 2433 | 0.130 |
Why?
|
| Neoplasms | 1 | 2022 | 447 | 0.130 |
Why?
|
| Health Policy | 1 | 2018 | 101 | 0.130 |
Why?
|
| Liver | 1 | 2017 | 31 | 0.130 |
Why?
|
| Gene Library | 1 | 2017 | 4 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 5 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2014 | 635 | 0.130 |
Why?
|
| Calcium, Dietary | 3 | 2007 | 28 | 0.130 |
Why?
|
| Suicidal Ideation | 3 | 2024 | 98 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 28 | 0.130 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 92 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2017 | 17 | 0.130 |
Why?
|
| Menarche | 2 | 2009 | 26 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 42 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2017 | 23 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2018 | 242 | 0.120 |
Why?
|
| Viral Load | 1 | 2017 | 141 | 0.120 |
Why?
|
| Sex Distribution | 2 | 2017 | 164 | 0.120 |
Why?
|
| Age Distribution | 2 | 2017 | 221 | 0.120 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1233 | 0.120 |
Why?
|
| Disease Progression | 2 | 2026 | 252 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 1887 | 0.110 |
Why?
|
| Cause of Death | 3 | 2021 | 171 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2026 | 657 | 0.100 |
Why?
|
| Age Factors | 4 | 2019 | 814 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2012 | 5 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 6 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2015 | 235 | 0.090 |
Why?
|
| Skinfold Thickness | 3 | 2006 | 18 | 0.090 |
Why?
|
| Minority Groups | 2 | 2023 | 99 | 0.080 |
Why?
|
| Biomarkers | 2 | 2025 | 284 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2012 | 120 | 0.080 |
Why?
|
| Prognosis | 3 | 2020 | 568 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2022 | 995 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 1058 | 0.080 |
Why?
|
| Iron, Dietary | 2 | 2007 | 7 | 0.080 |
Why?
|
| Dietary Fiber | 2 | 2007 | 60 | 0.070 |
Why?
|
| Depression | 2 | 2024 | 479 | 0.070 |
Why?
|
| Asian Americans | 2 | 2020 | 146 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 2007 | 4 | 0.060 |
Why?
|
| Body Fat Distribution | 1 | 2007 | 4 | 0.060 |
Why?
|
| Dietary Sucrose | 1 | 2007 | 13 | 0.060 |
Why?
|
| Nutrition Policy | 1 | 2007 | 18 | 0.060 |
Why?
|
| Skin | 1 | 2007 | 12 | 0.060 |
Why?
|
| Sunlight | 1 | 2007 | 13 | 0.060 |
Why?
|
| European Continental Ancestry Group | 2 | 2020 | 400 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2007 | 23 | 0.060 |
Why?
|
| Smoking | 2 | 2022 | 373 | 0.060 |
Why?
|
| Vitamin D | 1 | 2007 | 75 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 247 | 0.060 |
Why?
|
| Asia | 1 | 2006 | 11 | 0.060 |
Why?
|
| Folic Acid | 1 | 2006 | 29 | 0.060 |
Why?
|
| Diet Surveys | 1 | 2006 | 56 | 0.060 |
Why?
|
| Propensity Score | 1 | 2026 | 78 | 0.060 |
Why?
|
| Mitochondria | 1 | 2025 | 5 | 0.060 |
Why?
|
| Milk | 1 | 2004 | 8 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 653 | 0.050 |
Why?
|
| Smoke | 1 | 2024 | 7 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2024 | 1 | 0.050 |
Why?
|
| Pruritus | 1 | 2023 | 2 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2024 | 11 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 796 | 0.050 |
Why?
|
| Bone Density | 1 | 2004 | 93 | 0.050 |
Why?
|
| Infant Formula | 1 | 2003 | 10 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2024 | 75 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 30 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 20 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 198 | 0.050 |
Why?
|
| Population Groups | 1 | 2023 | 7 | 0.050 |
Why?
|
| Body Weight | 1 | 2004 | 197 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 311 | 0.050 |
Why?
|
| Mutation | 2 | 2014 | 86 | 0.050 |
Why?
|
| Health Promotion | 1 | 2006 | 277 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 63 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 145 | 0.050 |
Why?
|
| Exercise | 2 | 2004 | 513 | 0.050 |
Why?
|
| Child Health | 1 | 2023 | 41 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2022 | 2 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2007 | 261 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 10 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 226 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 18 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 29 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 75 | 0.040 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 30 | 0.040 |
Why?
|
| Mammography | 2 | 2011 | 141 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 66 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 104 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 569 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 3 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 376 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 42 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 816 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2023 | 1430 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 44 | 0.030 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 176 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2020 | 350 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 92 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 6 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 4 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2020 | 418 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 34 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 315 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 571 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 140 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 332 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 560 | 0.030 |
Why?
|
| Body Composition | 2 | 2007 | 90 | 0.030 |
Why?
|
| Pacific States | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 670 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 163 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 51 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 80 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 33 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 103 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 693 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2015 | 255 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 322 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 94 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 110 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 207 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 58 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 40 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 210 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 291 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 244 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 104 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 346 | 0.020 |
Why?
|
| Polynesia | 1 | 2009 | 2 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 17 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2007 | 20 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 28 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 45 | 0.020 |
Why?
|
| Diet Records | 1 | 2007 | 37 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 6 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2007 | 88 | 0.020 |
Why?
|
| Energy Intake | 1 | 2007 | 98 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2007 | 120 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2004 | 56 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 71 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 237 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 36 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 54 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 146 | 0.010 |
Why?
|
Concepts
(271)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->